The Food and Drug Administration (FDA) is tasked with ensuring the safety and effectiveness of medicine. FDA's science base must be strong enough to make certain that regulatory decisions are based on the best scientific evidence. The IOM held a public workshop on February 26, 2010, to examine the state of regulatory science and to consider approaches for enhancing it.
Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health
Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb
Institute of Medicine, Board on Health Promotion and Disease Prevention, Michael A. Stoto, Barbara Loe Fisher, Richard B. Johnston, Ann Bostrom, Geoffrey Evans
and Medicine National Academies of Sciences, Engineering, Institute of Medicine, Board on Health Sciences Policy, Committee on the Ethical and Social Policy Considerations of Novel Techniques for Prevention of Maternal Transmission of Mitochondrial DNA Diseases, Jeffrey Kahn, Rebecca English, Anne Claiborne
Institute of Medicine, Board on Health Sciences Policy, and Translation Forum on Drug Discovery, Development, Robert B. Giffin, Yeonwoo Lebovitz, Rebecca A. English
Academy of Science of South Africa, Institute of Medicine, Board on Health Sciences Policy, and Translation Forum on Drug Discovery, Development, Anne Claiborne, Yeonwoo Lebovitz, Steve Olson
and Medicine National Academies of Sciences, Engineering, Health and Medicine Division, Board on Health Care Services, Board on Health Sciences Policy, Committee on Temporomandibular Disorders (TMDs): From Research Discoveries to Clinical Treatment, Olivia Yost, Cathy T. Liverman, Rebecca English, Sean Mackey, Enriqueta C. Bond